AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25116969 — intervention group
Group type: COMPARATOR
Intervention: Visible light (sham treatment)
Number of subjects: 21
Study 23017045 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 126
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy led exercise class
Number of subjects: 0
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness instructor led exercise class
Number of subjects: 0
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist led intervention (Strand B)
Number of subjects: 0
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention led by Physiotherapist (Strand B)
Number of subjects: 0
Study 19607666 — intervention group
Group type: EXPERIMENTAL
Intervention: Group yoga intervention (Strand B)
Number of subjects: 0
Study 19607666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in exercise habits)
Number of subjects: 0
Study 17768662 — intervention group
Group type: EXPERIMENTAL
Intervention: Axin overexpression in BE1 cells (BE1-axin cells)
Number of subjects: 107
Study 17768662 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-transfected BE1 cells)
Number of subjects: 107
Study 15035598 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 15035598 — intervention group
Group type: COMPARATOR
Intervention: Control (Inhaled corticosteroid therapy)
Number of subjects: 0
Study 12453333 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 0
Study 12453333 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 12453333 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-based chemotherapy with radiation
Number of subjects: 0
Study 11475715 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BHD) combined with western medicine (prednisone acetate and cytoxan)
Number of subjects: 70
Study 11475715 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (prednisone acetate and cytoxan) with aspirin and persantin
Number of subjects: 70
Study 11475715 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 70
Study 7544731 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment for 5 years
Number of subjects: 55
Study 31112079 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 µg applied vaginally 10 hours and 4 hours prior to IUD insertion
Number of subjects: 90
Study 31112079 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet applied vaginally 10 hours and 4 hours prior to IUD insertion
Number of subjects: 90
Study 31112079 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 90
Study 31112079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28319872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) bolus injection, 50-μg
Number of subjects: 36
Study 28319872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 25878371 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (500 mg) of IV methylprednisolone
Number of subjects: 0
Study 25878371 — intervention group
Group type: COMPARATOR
Intervention: 10 days of oral prednisolone
Number of subjects: 0
Study 23261871 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy-dense (high-ED) food cues in fed state
Number of subjects: 0
Study 23261871 — intervention group
Group type: COMPARATOR
Intervention: Low energy-dense (low-ED) food cues in fed state
Number of subjects: 0
Study 23261871 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy-dense (high-ED) food cues in fasted state
Number of subjects: 0
Study 23261871 — intervention group
Group type: COMPARATOR
Intervention: Low energy-dense (low-ED) food cues in fasted state
Number of subjects: 0
Study 21612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made metal postcore (CMPC)
Number of subjects: 75
Study 21612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated fiber postcore (PFPC)
Number of subjects: 75
Study 21612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made fiber postcore (CFPC)
Number of subjects: 75
Study 21612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally tilted restorations
Number of subjects: 75
Study 21612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingually tilted restorations
Number of subjects: 75
Study 19918859 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 73
Study 19918859 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) ointment
Number of subjects: 73
Study 17005502 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMISE programme (treatment group)
Number of subjects: 62
Study 17005502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 12773076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study 11072556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber/pectin
Number of subjects: 44
Study 11072556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-free/placebo
Number of subjects: 44
Study 11072556 — intervention group
Group type: COMPARATOR
Intervention: Fiber/placebo
Number of subjects: 44
Study 11072556 — intervention group
Group type: COMPARATOR
Intervention: Fiber
Number of subjects: 44
Study 9863109 — intervention group
Group type: EXPERIMENTAL
Intervention: RBUD-1 (a preparation of Chinese herbal medicine)
Number of subjects: 122
Study 9863109 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite prescription of Western and Chinese medicine
Number of subjects: 122
Study 9863109 — intervention group
Group type: COMPARATOR
Intervention: Lasix or mineral water (control group)
Number of subjects: 122
Study 8280685 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 micrograms NODS
Number of subjects: 28
Study 8280685 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 micrograms NODS
Number of subjects: 28
Study 8280685 — intervention group
Group type: EXPERIMENTAL
Intervention: 124 micrograms NODS
Number of subjects: 28
Study 8280685 — intervention group
Group type: COMPARATOR
Intervention: 35 microliters of 0.5% proxymetacaine drops (175 micrograms)
Number of subjects: 28
Study 3549583 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 32
Study 3549583 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 32
Study 31343518 — intervention group
Group type: COMPARATOR
Intervention: No virtual opponent (NO)
Number of subjects: 12
Study 31343518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low athlete‐opponent interdependency (OP‐IND)
Number of subjects: 12
Study 31343518 — intervention group
Group type: EXPERIMENTAL
Intervention: High athlete‐opponent interdependency (OP‐DEP)
Number of subjects: 12
Study 30457358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose treatment
Number of subjects: 0
Study 30457358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27789414 — intervention group
Group type: EXPERIMENTAL
Intervention: ASBI implementation program (including e-learning module, tailored feedback module, and environmental support)
Number of subjects: 0
Study 27789414 — intervention group
Group type: EXPERIMENTAL
Intervention: ASBI implementation program
Number of subjects: 0
Study 27789414 — intervention group
Group type: COMPARATOR
Intervention: Control group (GPs not receiving the ASBI implementation program)
Number of subjects: 0
Study 24597472 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3 mg weekly for the first 7 weeks, then 2 mg, adjusted to 1.5 mg for certain patients)
Number of subjects: 3773
Study 24597472 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (daily with dose adjustment to maintain INR between 2.0 and 3.0)
Number of subjects: 3773
Study 24597472 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux
Number of subjects: 3773
Study 24597472 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3773
Study 22613182 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based screening and brief intervention via eScreen.se
Number of subjects: 202
Study 22613182 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 202
Study 21169087 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scan before treatment
Number of subjects: 35
Study 21169087 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scan after 6 months of treatment
Number of subjects: 35
Study 21169087 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria
Number of subjects: 35
Study 19932833 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG) 4 g, applied 4 times daily for 12 weeks
Number of subjects: 492
Study 19932833 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) 4 g, applied 4 times daily for 12 weeks
Number of subjects: 492
Study 15899444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 30
Study 15899444 — intervention group
Group type: COMPARATOR
Intervention: Cyclopentolate 1%
Number of subjects: 30
Study 12609785 — intervention group
Group type: EXPERIMENTAL
Intervention: LHA formulation (2-hydroxy-5-octanoyl benzoic acid), applied twice daily for 2 weeks
Number of subjects: 14
Study 12609785 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 14
Study 10338051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized local anaesthesia (LA) solution (n = 19)
Number of subjects: 40
Study 10338051 — intervention group
Group type: COMPARATOR
Intervention: Non-alkalinized local anaesthesia (LA) solution (n = 21)
Number of subjects: 40
Study 10338051 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream with local anaesthesia and patient-controlled analgesia with alfentanil
Number of subjects: 40
Study 8520498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A (3 mega units/m2 s.c. three times weekly)
Number of subjects: 84
Study 8520498 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 84
Study 8520498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A
Number of subjects: 84
Study 8520498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A (started in 45 patients at a median of 62 days after HDM)
Number of subjects: 84
Study 1951587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 120
Study 1951587 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120
Study 7203334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 micrograms/kg body weight and 0.5 micrograms/kg body weight)
Number of subjects: 30
Study 7203334 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.5 mg per single dose)
Number of subjects: 30
Study 7203334 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine (1 mg)
Number of subjects: 30
Study 31444080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-monovision group (nondominant eye targeted for -0.50 D)
Number of subjects: 79
Study 31444080 — intervention group
Group type: COMPARATOR
Intervention: Emmetropia group (both eyes targeted for emmetropia)
Number of subjects: 79
Study 31444080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 29725805 — intervention group
Group type: EXPERIMENTAL
Intervention: TURBT + tamsulosin (Group 1)
Number of subjects: 95
Study 29725805 — intervention group
Group type: COMPARATOR
Intervention: TURBT + TURP (Group 2)
Number of subjects: 95
Study 27399494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery to a surgical cavity (SRS‐cav)
Number of subjects: 131
Study 27399494 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 131
Study 27399494 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS‐cav
Number of subjects: 131
Study 27399494 — intervention group
Group type: COMPARATOR
Intervention: OBS
Number of subjects: 131
Study 24597650 — intervention group
Group type: EXPERIMENTAL
Intervention: RehabMaster intervention (30 minutes per day for two weeks)
Number of subjects: 23
Study 24597650 — intervention group
Group type: EXPERIMENTAL
Intervention: RehabMaster intervention plus conventional occupational therapy (10 sessions)
Number of subjects: 23
Study 24597650 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy only (OT-only group)
Number of subjects: 23
Study 22204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol AUCi
Number of subjects: 20
Study 20073567 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment (ISE), n = 58
Number of subjects: 189
Study 20073567 — intervention group
Group type: COMPARATOR
Intervention: Individual Placement and Support (IPS), n = 65
Number of subjects: 189
Study 20073567 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR), n = 66
Number of subjects: 189
Study 17331969 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) during walking
Number of subjects: 20
Study 17331969 — intervention group
Group type: COMPARATOR
Intervention: No noninvasive positive-pressure ventilation (without NPPV) during walking
Number of subjects: 20
Study 15914127 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort 300 mg three times daily
Number of subjects: 16
Study 15914127 — intervention group
Group type: COMPARATOR
Intervention: Low-dose OC (Loestrin 1/20) with placebo
Number of subjects: 16
Study 12626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen-progestin therapy (1 mg 17beta-estradiol with 500 micro g norethisterone acetate daily)
Number of subjects: 72
Study 12626213 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg daily)
Number of subjects: 72
Study 10337434 — intervention group
Group type: EXPERIMENTAL
Intervention: Patanol (olopatadine hydrochloride 0.1% ophthalmic solution)
Number of subjects: 15
Study 10337434 — intervention group
Group type: COMPARATOR
Intervention: Claritin (loratadine, 10 mg tablet)
Number of subjects: 15
Study 8527539 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 3 days)
Number of subjects: 42
Study 8527539 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg daily for 3 days)
Number of subjects: 42
Study 2257072 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (somatropin)
Number of subjects: 12
Study 2257072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 2257072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 12
Study 7279423 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 153
Study 7279423 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 153
Study 7279423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 29155291 — intervention group
Group type: EXPERIMENTAL
Intervention: QUAL‐EC‐P questionnaire
Number of subjects: 183
Study 27956565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 146
Study 27956565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 24425697 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical services treatment for ACS
Number of subjects: 871
Study 23727163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876
Study 23727163 — intervention group
Group type: COMPARATOR
Intervention: No IPC (control group)
Number of subjects: 2876
Study 23727163 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 2876
Study 20417572 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance group (optimal therapeutic doses continued throughout the study)
Number of subjects: 404
Study 20417572 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-week group (optimal therapeutic doses continued for 26 weeks, followed by a 50% dose reduction maintained until the end of the study)
Number of subjects: 404
Study 20417572 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group (optimal therapeutic doses continued for 4 weeks, followed by a 50% dose reduction maintained until the end of the study)
Number of subjects: 404
Study 20417572 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatment groups
Number of subjects: 404
Study 18355330 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisin consumption (90 g/day)
Number of subjects: 17
Study 18355330 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (264 kcal/day)
Number of subjects: 17
Study 16627548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 28
Study 16627548 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy plus placebo medication
Number of subjects: 28
Study 12648967 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal home visits by nurse-midwives (5 structured visits)
Number of subjects: 139
Study 12648967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 139
Study 11034122 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded toothbrush 1
Number of subjects: 18
Study 11034122 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded toothbrush 2
Number of subjects: 18
Study 11034122 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with convex filament head arrangement
Number of subjects: 18
Study 11034122 — intervention group
Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 18
Study 9103748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger treatment (12-session cognitive-behavioral treatment)
Number of subjects: 15
Study 9103748 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care control
Number of subjects: 15
Study 9103748 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (18 months)
Number of subjects: 15
Study 1391667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine
Number of subjects: 96
Study 1391667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3902480 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside (40 mg/day i.m. injection) for 6 weeks
Number of subjects: 40
Study 3902480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31112941 — intervention group
Group type: EXPERIMENTAL
Intervention: aLiFE program (Lifestyle‐integrated Functional Exercise)
Number of subjects: 30
Study 30172407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr supplementation (0.05 mg of Cr/kg of body weight0.75)
Number of subjects: 24
Study 30172407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Cr supplement; Cr‐)
Number of subjects: 24
Study 27310977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg bid), levofloxacin (500 mg once daily), omeprazole (40 mg bid), doxycycline (100 mg twice daily) for 14 days
Number of subjects: 100
Study 27310977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide-based regimen
Number of subjects: 100
Study 24902655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized goal-directed therapy (IGDT) with transthoracic echocardiography (TTE) and pulse-contour device (FloTrac™)
Number of subjects: 50
Study 24902655 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 50
Study 24902655 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized goal-directed therapy (IGDT)
Number of subjects: 50
Study 23558875 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA therapy
Number of subjects: 293
Study 23558875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma SA concentration
Number of subjects: 293
Study 20816468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimigrainous medication for treating single attacks and preventing recurring attacks
Number of subjects: 0
Study 20816468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18755550 — intervention group
Group type: EXPERIMENTAL
Intervention: High time spent with smoking parents
Number of subjects: 67
Study 18755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low time spent with smoking parents
Number of subjects: 67
Study 18755550 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking parents
Number of subjects: 67
Study 18755550 — intervention group
Group type: COMPARATOR
Intervention: Overall correlation with parental smoking exposure
Number of subjects: 67
Study 15725422 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg levodopa
Number of subjects: 40
Study 15725422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12882902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 102
Study 12882902 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 102
Study 10429625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin
Number of subjects: 0
Study 10429625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and continuous infusion of etoposide with growth factor
Number of subjects: 0
Study 10429625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ifosfamide and doxorubicin treatment after primary surgery
Number of subjects: 0
Study 10429625 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy for localized resectable STS
Number of subjects: 0
Study 8666123 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest® (adhesive matrix transdermal system) used in combination with dydrogesterone for 12 days in each cycle
Number of subjects: 0
Study 8666123 — intervention group
Group type: COMPARATOR
Intervention: Menorest®
Number of subjects: 0
Study 8666123 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest® (twice weekly application)
Number of subjects: 0